PT3439661T - Métodos de tratamento de condições oculares - Google Patents

Métodos de tratamento de condições oculares

Info

Publication number
PT3439661T
PT3439661T PT177183043T PT17718304T PT3439661T PT 3439661 T PT3439661 T PT 3439661T PT 177183043 T PT177183043 T PT 177183043T PT 17718304 T PT17718304 T PT 17718304T PT 3439661 T PT3439661 T PT 3439661T
Authority
PT
Portugal
Prior art keywords
methods
treating ocular
ocular conditions
conditions
treating
Prior art date
Application number
PT177183043T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Publication of PT3439661T publication Critical patent/PT3439661T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT177183043T 2016-04-07 2017-04-06 Métodos de tratamento de condições oculares PT3439661T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662319648P 2016-04-07 2016-04-07

Publications (1)

Publication Number Publication Date
PT3439661T true PT3439661T (pt) 2021-09-30

Family

ID=58549326

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177183043T PT3439661T (pt) 2016-04-07 2017-04-06 Métodos de tratamento de condições oculares

Country Status (20)

Country Link
US (3) US10709707B2 (enExample)
EP (2) EP3439661B1 (enExample)
JP (3) JP7090551B2 (enExample)
KR (2) KR102512777B1 (enExample)
CN (3) CN109310692B (enExample)
AU (1) AU2017248276B2 (enExample)
CA (1) CA3020170A1 (enExample)
DK (1) DK3439661T3 (enExample)
EA (1) EA201892265A1 (enExample)
ES (1) ES2893126T3 (enExample)
IL (3) IL299204A (enExample)
MX (2) MX385698B (enExample)
MY (1) MY199237A (enExample)
NZ (1) NZ746468A (enExample)
PH (1) PH12018502154A1 (enExample)
PT (1) PT3439661T (enExample)
SG (1) SG11201808650QA (enExample)
TW (2) TWI790997B (enExample)
WO (1) WO2017177024A1 (enExample)
ZA (1) ZA201807438B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
PT3848028T (pt) 2014-10-20 2024-09-20 Oyster Point Pharma Inc Métodos de tratamento de estados oculares
DK3439661T3 (da) 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
EP3820443A1 (en) 2018-07-10 2021-05-19 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
ES3039903T3 (en) * 2020-04-28 2025-10-27 Oyster Point Pharma Inc Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
EP4333855A4 (en) * 2021-05-07 2025-07-09 Oyster Point Pharma Inc CO-THERAPY WITH A VECTOR AND A NICOTINIC AGONIST

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
KR20040066140A (ko) 2001-11-29 2004-07-23 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]헥사데카-2(11),3,5,7,9-펜타엔의 숙신산염 및 그의 제약 조성물
WO2004039366A1 (en) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2583101A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
WO2006100075A2 (en) 2005-03-22 2006-09-28 Niconovum Ab Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
CA2676670C (en) 2007-02-02 2012-03-13 Pfizer Products Inc. Tricyclic compounds, compositions, and methods
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
CA2716863A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
EP2344496A1 (en) 2008-09-05 2011-07-20 Targacept Inc. Amides of diazabicyclooctanes and uses thereof
JP2012505834A (ja) * 2008-10-14 2012-03-08 サイコジェニックス・インコーポレーテッド ニコチン性アセチルコリン受容体リガンドおよびその使用
ES2820857T3 (es) 2008-12-01 2021-04-22 Oyster Point Pharma Inc Síntesis y formas de sal novedosas de (R)-5-((E)-2-pirrolidin-3-ilvinil)pirimidina
US9145396B2 (en) * 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
CA2763551A1 (en) * 2009-06-17 2010-12-23 Targacept, Inc. Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
CA3083244C (en) 2011-10-20 2023-01-03 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
WO2013080196A1 (en) 2011-11-30 2013-06-06 D.E.S. Diagnostics Ltd. Dry eye diagnostic
PT3848028T (pt) * 2014-10-20 2024-09-20 Oyster Point Pharma Inc Métodos de tratamento de estados oculares
DK3439661T3 (da) * 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser

Also Published As

Publication number Publication date
MY199237A (en) 2023-10-22
EP3439661A1 (en) 2019-02-13
US20200345734A1 (en) 2020-11-05
KR102512777B1 (ko) 2023-03-23
EA201892265A1 (ru) 2019-04-30
US20250000861A1 (en) 2025-01-02
NZ746468A (en) 2023-06-30
TW201737917A (zh) 2017-11-01
IL299204A (en) 2023-02-01
CN114533737B (zh) 2024-05-31
JP2022120125A (ja) 2022-08-17
TWI790997B (zh) 2023-02-01
SG11201808650QA (en) 2018-10-30
EP3970724A1 (en) 2022-03-23
KR20190005859A (ko) 2019-01-16
AU2017248276B2 (en) 2023-07-13
MX2018012230A (es) 2019-03-28
CN109310692B (zh) 2022-01-25
KR102485299B1 (ko) 2023-01-06
MX385698B (es) 2025-03-18
CN114432313A (zh) 2022-05-06
ZA201807438B (en) 2024-09-25
KR20230010813A (ko) 2023-01-19
WO2017177024A8 (en) 2018-11-08
IL290069A (en) 2022-03-01
IL290069B2 (en) 2023-05-01
IL262102A (en) 2018-11-29
WO2017177024A1 (en) 2017-10-12
DK3439661T3 (da) 2021-10-18
US20190201397A1 (en) 2019-07-04
EP3439661B1 (en) 2021-08-04
NZ785093A (en) 2024-07-05
ES2893126T8 (es) 2022-05-23
JP2024103594A (ja) 2024-08-01
JP7090551B2 (ja) 2022-06-24
TW202320785A (zh) 2023-06-01
TWI876258B (zh) 2025-03-11
PH12018502154A1 (en) 2019-07-08
US10709707B2 (en) 2020-07-14
CA3020170A1 (en) 2017-10-12
AU2017248276A1 (en) 2018-11-22
CN109310692A (zh) 2019-02-05
CN114533737A (zh) 2022-05-27
BR112018070497A2 (pt) 2019-01-29
MX2021010399A (es) 2022-01-18
IL290069B1 (en) 2023-01-01
ES2893126T3 (es) 2022-02-08
IL262102B (en) 2022-03-01
JP2019513759A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL253244B1 (en) Methods for treating retinal diseases
IL290069A (en) Methods for treating eye conditions
IL267229A (en) Methods of treating ocular disorders
ZA201706059B (en) Method of treatment with tradipitant
ZA201903873B (en) Methods of treating cochlear synaptopathy
IL251769A0 (en) Methods for treating eye conditions
ZA201705877B (en) Method of treating diseases
EP3684342C0 (en) TREATMENT PROCEDURES
LT3661510T (lt) Elgesio pakitimų gydymo būdai
IL254825A0 (en) Methods of treatment with Tesalisib
GB201715654D0 (en) Method of treatment
GB201706406D0 (en) Method of treatment
EP3491129A4 (en) METHODS OF TREATING OSMIDROSIS
IL253847A0 (en) Methods of treating diseases
IL270362B (en) Glaucoma treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201602802D0 (en) Method of treatment
GB201512139D0 (en) Methods of treatment
HK40004067A (en) Methods of treating ocular conditions
PT3661510T (pt) Métodos de tratamento de alterações do comportamento
GB201718589D0 (en) Method of treatment
GB201709554D0 (en) Method of treatment
GB201706642D0 (en) Method of treatment